Genmab and Janssen Biotech Report Initiation of P-III MMY3021 Study for Darzalex (daratumumab) in Multiple Myeloma

 Genmab and Janssen Biotech Report Initiation of P-III MMY3021 Study for Darzalex (daratumumab) in Multiple Myeloma

Genmab and Janssen Biotech Report Initiation of P-III MMY3021 Study for Darzalex (daratumumab) in Multiple Myeloma

Shots:

  • The P-III MMY3021 study involves assessing of daratumumab (1800mg, SC) + lenalidomide vs lenalidomide as monothx. in 214 newly diagnosed multiple myeloma patients who are MRD + after autologous stem cell transplant (ASCT) with no prior anti-CD38 exposure
  • In H1’19 the companies plan to initiate the P-III MMY3021 study for daratumumab with 1EPs as MRD conversion rate, from MRD positive to MRD negative in 12mos. for 36 cycles
  • Darzalex (daratumumab,1800 mg, SC) is an IgG1k mAb binds with CD38 molecule targeting the tumor cells death via immunomodulatory action and has received FDA’s BT designation for multiple myeloma. In Aug,2012 Janssen acquired exclusive WW rights to develop, manufacture and commercialize daratumumab

Click here to read full press release/ article | Ref: Genmab | Image: PM Live

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post